These innovative molecules represent a significant advancement in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose https://orlandoimuc279716.blog-eye.com/39444806/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide